# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# Analysis 1.17

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 17: Any adverse events for induction of remission in UC

# Analysis 1.18

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 18: Induction of endoscopic remission in UC at longest follow-up

# Analysis 1.19

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 19: Quality of life (Inflammatory Bowel Disease Questionnaire [IBDQ]) scores at longest follow-up for induction of remission in UC

# Analysis 1.20

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 20: Quality of life (IBDQ) scores at longest follow-up for induction of remission in UC: sensitivity analysis without Haifer 2022

# Analysis 1.21

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 21: Induction of clinical response in UC at longest follow-up

# Analysis 1.22

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 22: Induction of endoscopic response in UC at longest follow-up

# Analysis 1.23

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 23: Withdrawals in studies on induction of remission in UC

# Analysis 1.24

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 24: Erythrocyte sedimentation rate (ESR) at longest follow-up for induction of remission in UC (mm/hour)

# Analysis 1.25

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 25: ESR at longest follow-up for induction of remission in UC: sensitivity analysis without Moayyedi 2015 (mm/hour)

# Analysis 1.26

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 26: C-reactive protein (CRP) at longest follow-up for induction of remission in UC (mg/L)

# Analysis 1.27

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 27: CRP at longest follow-up for induction of remission in UC: sensitivity analysis without Moayyedi 2015 (mg/L)

# Analysis 1.28

Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 28: Fecal calprotectin at longest follow-up for induction of remission in UC (μg/mg)

# Analysis 2.1

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 1: Maintenance of clinical remission in UC

# Analysis 2.2

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 2: Maintenance of clinical remission in UC: sensitivity analysis using fixed-effect model

# Analysis 2.3

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 3: Maintenance of clinical remission in UC: sensitivity analysis for available cases

# Analysis 2.4

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 4: Serious adverse events for maintenance of remission in UC

# Analysis 2.5

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 5: Any adverse events for maintenance of remission in UC

# Analysis 2.6

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 6: Maintenance of endoscopic remission in UC

# Analysis 2.7

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 7: Withdrawals in studies on maintenance of remission in UC

# Analysis 2.8

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 8: Erythrocyte sedimentation rate (ESR) at longest follow-up for maintenance of remission in UC (mm/hour)

# Analysis 2.9

Comparison 2: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in ulcerative colitis (UC), Outcome 9: C-reactive protein (CRP) at longest follow-up for maintenance of remission in UC (mg/L)

# Analysis 4.1

Comparison 4: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in Crohn's disease (CD), Outcome 1: Maintenance of clinical remission in CD

# Analysis 4.2

Comparison 4: Fecal microbiota transplantation (FMT) versus control for maintenance of remission in Crohn's disease (CD), Outcome 2: Withdrawals in studies on maintenance of remission in CD

# ADDITIONAL TABLES

120

# APPENDICES

129

# WHAT'S NEW

131

# HISTORY

131

# CONTRIBUTIONS OF AUTHORS

131

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.